Structural biology (SB) provides a critical drug discovery and development tool for accurately identifying and understanding the structure of a target. Alessandro Piai, PhD, Principal Research Scientist at IRBM, describes the company’s expertise in nuclear magnetic resonance (NMR) and how it can be leveraged to accelerate the identification of molecules for progression to the clinic.
The UK is purchasing 30 million doses of the Coronavirus vaccine, which has been developed by the University of Oxford in partnership with the Italian IRBM, based in Pomezia (Rome). This is the only known agreement of that sort between a country and AstraZeneca, and it could provide a significant advantage to the UK with regard to public health and economic recovery, if the vaccine proves effective. It is unclear if also Italy is currently negotiating with AstraZeneca.
Article by Antonello Guerrera published on la Repubblica – 18/05/2020